Artículos por temáticas

Post-Ischemic Brain Neurodegeneration in the Form of Alzheimer's Disease Proteinopathy: Possible Therapeutic Role of Curcumin

Pluta R, Furmaga-Jabłońska W, Januszewski S, Czuczwar SJ.

Nutrients. 2022 Jan 7;14(2):248. doi: 10.3390/nu14020248.

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

Kopp KO, Glotfelty EJ, Li Y, Greig NH.

Pharmacol Res. 2022 Dec;186:106550. doi: 10.1016/j.phrs.2022.106550. Epub 2022 Nov 11.

Potential role of IP3/Ca(2+) signaling and phosphodiesterases: Relevance to neurodegeneration in Alzheimer's disease and possible therapeutic strategies

Jyoti Dutta B, Singh S, Seksaria S, Das Gupta G, Bodakhe SH, Singh A.

Biochem Pharmacol. 2022 Jul;201:115071. doi: 10.1016/j.bcp.2022.115071. Epub 2022 May 4.

Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease

Andrade C.

J Clin Psychiatry. 2022 Feb 1;83(1):22f14398. doi: 10.4088/JCP.22f14398.

Icariin: A Potential Neuroprotective Agent in Alzheimer's Disease and Parkinson's Disease

Khezri MR, Ghasemnejad-Berenji M.

Neurochem Res. 2022 Oct;47(10):2954-2962. doi: 10.1007/s11064-022-03667-0. Epub 2022 Jul 8.

Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training

De Sousa RAL, Improta-Caria AC.

Metab Brain Dis. 2022 Mar;37(3):559-580. doi: 10.1007/s11011-022-00903-y. Epub 2022 Jan 25.

Testosterone, cognitive decline and dementia in ageing men

Yeap BB, Flicker L.

Rev Endocr Metab Disord. 2022 Dec;23(6):1243-1257. doi: 10.1007/s11154-022-09728-7. Epub 2022 May 28.

Implication of Covid-19 on Neurological Complications with Specific Emphasis on Alzheimer's and Parkinson's Disease

Sood A, Goyal R, Singh H, Behl T, Arora S, Saini B, Kaur R.

CNS Neurol Disord Drug Targets. 2022;21(3):235-245. doi: 10.2174/1871527320666210820092817.

The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease

Shen S, Liao Q, Wong YK, Chen X, Yang C, Xu C, Sun J, Wang J.

Int J Biol Sci. 2022 Jan 1;18(3):983-994. doi: 10.7150/ijbs.66871. eCollection 2022.

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

Mahapatra MK, Karuppasamy M, Sahoo BM.

Pharm Res. 2022 Jun;39(6):1233-1248. doi: 10.1007/s11095-022-03302-1. Epub 2022 Jun 1.

Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease

Goyal A, Verma A, Dubey N, Raghav J, Agrawal A.

J Food Biochem. 2022 Dec;46(12):e14415. doi: 10.1111/jfbc.14415. Epub 2022 Sep 15.

Targeting endoplasmic reticulum stress using natural products in neurological disorders

Jangra A, Verma M, Kumar D, Chandrika, Rachamalla M, Dey A, Dua K, Jha SK, Ojha S, Alexiou A, Kumar D, Jha NK.

Neurosci Biobehav Rev. 2022 Oct;141:104818. doi: 10.1016/j.neubiorev.2022.104818. Epub 2022 Aug 5.

Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer's Disease: A Structured Literature Review

Benca R, Herring WJ, Khandker R, Qureshi ZP.

J Alzheimers Dis. 2022;86(1):83-109. doi: 10.3233/JAD-215324.

Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia

Linh TTD, Hsieh YC, Huang LK, Hu CJ.

Int J Mol Sci. 2022 Sep 21;23(19):11067. doi: 10.3390/ijms231911067.

Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature

Alhowail A, Alsikhan R, Alsaud M, Aldubayan M, Rabbani SI.

Drug Des Devel Ther. 2022 Aug 31;16:2919-2931. doi: 10.2147/DDDT.S367229. eCollection 2022.